Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Laboratory consumables and reagents / Clinical-development sample handling and biobanking consumables

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Clinical-development sample handling and biobanking consumables

Single-use sample collection, cryovials, storage plates, aliquot bags, shipping containers, filtration and general laboratory chemicals bought by pharmaceutical clinical-development functions and their CRO partners to collect, process, store and ship clinical trial samples. Segmented by buyer organisation type (pharma clinical development and clinical-stage CROs) and the job of maintaining sample integrity from collection through biobanking. Excludes discovery assay work (niche 1), scale-up purification (niche 2), routine contract QC (niche 3) and academic research (niche 4).

Market size
$9.0B
$9.0B ($7.2B–$10.8B) · 2026 · Bottom-up
Growth
+6.0%
$12.0B by 2031
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
4 sources · Bottom-up
Level
Niche
Segmented by
Customer type
Buyers
Clinical development and clinical operations functions of pharmaceutical and biotechnology companies; clinical-stage CRO sample-management teams
Buying centre
Clinical operations or biobanking manager owns the workflow; sourcing handled by clinical supply chain or category procurement, frequently through validated vendor lists and quality-agreement review; quality assurance and regulatory affairs approve specifications
Buying triggers
  • Start-up of a new clinical trial or new country sites, triggering a fresh sample-handling basket
  • Expansion into new indications or new therapeutic modalities with different sample matrices
  • Biobanking build-out or migration to centralised sample storage
  • Regulatory or data-integrity findings requiring validated, traceable sample containers and records
Pains
  • Sample integrity failures (haemolysis, adsorption, temperature excursion) that can invalidate a whole biobank
  • Strict validation and quality-agreement requirements lengthening vendor onboarding
  • Multi-site standardisation gaps producing inconsistent sample handling across countries
  • Batch and expiry management complexity across long-duration, multi-year studies
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability—
Growth—

How this was sized

$9.0B ($7.2B–$10.8B) · 2026 · Bottom-up

Parent pool 2026 USD 60.4B (Emergen tools & reagents 2026 USD 109.77B [3] x 55% consumables-and-reagents share assumption; cross-check GVR 2026 USD 202.6B [1] x 30% = USD 60.8B; parent range USD 48-72B). Niche = parent x 15% assumed clinical sample-handling share = USD 9.1B, rounded to USD 9.0B; range USD 7.2-10.8B (parent range x 15%). Forecast: 9.0 x 1.06^5 = USD 12.0B by 2031, CAGR aligned with the 6.0% tools & reagents CAGR [3] and the 6.6% CAGR cited for the life science tools market in the HKEX industry overview [4].

Alongside it in Laboratory consumables and reagents

// Sell into Clinical-development sample handling and biobanking consumables

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.